<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Metabolic dysfunction-associated steatotic liver disease in pediatric patients: Definitions and phenotypes</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Metabolic dysfunction-associated steatotic liver disease in pediatric patients: Definitions and phenotypes</h1>
<div class="graphic"><div class="figure"><div class="ttl">Metabolic dysfunction-associated steatotic liver disease in pediatric patients: Definitions and phenotypes</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="20%"></colgroup><colgroup width="60%"></colgroup> <tbody> <tr> <td class="subtitle1_left">Term/phenotype<sup>[1]</sup></td> <td class="subtitle1_left">Previous nomenclature<sup>[2]</sup></td> <td class="subtitle1_left">Definitions</td> </tr> <tr> <td><strong>Steatotic liver disease</strong></td> <td>Fatty liver disease</td> <td> <ul> <li>Liver disease of any cause that results in hepatic steatosis (on imaging or biopsy).</li> </ul> </td> </tr> <tr class="highlight_lght_gray_text"> <td><strong>Metabolic dysfunction-associated steatotic liver disease (MASLD)</strong></td> <td>Nonalcoholic fatty liver disease (NAFLD)</td> <td> <ul> <li>Refers to steatotic liver disease associated with cardiometabolic dysfunction.</li> <li>Abnormal liver steatosis is typically defined as fat &gt;5% of the liver by imaging or histologic estimation.</li> <li>Requires the presence of at least 1 of 5 cardiometabolic risk factors<sup>*</sup>.</li> <li>The diagnosis of isolated MASLD requires the absence of significant alcohol (ie, &lt;140 g/week for females and &lt;210 g/week for males), monogenetic diseases, or medications that cause steatosis. MASLD may coexist with these other causes.</li> </ul> </td> </tr> <tr> <td><strong>Metabolic dysfunction-associated steatohepatitis (MASH)</strong></td> <td>Nonalcoholic steatohepatitis (NASH)</td> <td> <ul> <li>A definitive diagnosis of MASH can only be made by liver biopsy, but this is not always necessary for clinical management.</li> </ul> </td> </tr> <tr> <td class="indent1">Definite MASH</td> <td> </td> <td> <ul> <li>Hepatic steatosis with lobular inflammation, ballooning injury to hepatocytes, with or without fibrosis.</li> </ul> </td> </tr> <tr> <td class="indent1">Borderline MASH, zone 3 pattern</td> <td>Type 1</td> <td> <ul> <li>Has some but not all components of MASH injury, in a venule (zone 3)-centered injury pattern or confluent pattern.</li> </ul> </td> </tr> <tr> <td class="indent1">Borderline MASH, zone 1 pattern</td> <td>Type 2</td> <td> <ul> <li>Has some but not all components of MASH in a portal predominant (zone 1)-centered injury pattern, often without ballooning and more commonly seen in younger prepubertal children.</li> </ul> </td> </tr> <tr class="highlight_lght_gray_text"> <td><strong>MASLD with fibrosis or cirrhosis</strong></td> <td>NAFLD with fibrosis or cirrhosis</td> <td> <ul> <li>MASLD or MASH with periportal, portal, sinusoidal, or bridging fibrosis or cirrhosis.</li> </ul> </td> </tr> <tr> <td><strong>MASLD and increased alcohol intake (MetALD)</strong></td> <td>None (new category)</td> <td> <ul> <li>Moderate alcohol use is defined as 140 to 350 g/week for females and 210 to 420 g/week for males.</li> <li>This range of alcohol intake defines a spectrum between MASLD-predominant and alcohol-predominant disease.</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">Other terms such as "presumed NAFLD" (also "clinical NAFLD" or "suspected NAFLD") are terms used in the literature with varying meanings. These terms are often used when a biopsy has not been performed to confirm the diagnosis.</div><div class="graphic_footnotes"><p>A1C: glycated hemoglobin; BMI: body mass index; BP: blood pressure; HDL: high-density lipoprotein; MASH: metabolic dysfunction-associated steatohepatitis; MASLD: metabolic dysfunction-associated steatotic liver disease; MetALD: MASLD and increased alcohol intake; NAFLD: nonalcoholic fatty liver disease; NASH: nonalcoholic steatohepatitis.</p>
* Pediatric criteria for cardiometabolic risk factors are<sup>[1]</sup>:
<ul>
<li>Overweight/obesity – BMI ≥85<sup>th</sup> percentile for age/sex (BMI Z-score ≥+1) or waist circumference &gt;95<sup>th</sup> percentile (may vary by ethnicity or race).</li>
<li>Prediabetes/diabetes – A1C ≥5.7% (39 mmol/L), fasting serum glucose ≥100 mg/dL (5.6 mmol/L), random serum glucose ≥200 mg/dL (11.1 mmol/L), 2-hour oral glucose tolerance test ≥140 mg/dL (7.8 mmol/L), <strong>or</strong> established diagnosis of type 2 diabetes.</li>
<li>Hypertension – For age ≥13 years, BP ≥130/80 mmHg; for age &lt;13 years<sup>¶</sup>, BP ≥95<sup>th</sup> percentile or ≥130/80 (whichever is lower); <strong>or</strong> on antihypertensive treatment.</li>
<li>Hypertriglyceridemia – For age ≥10 years, triglyceride ≥150 mg/dL (1.7 mmol/L); for age &lt;10 years, triglyceride ≥100 mg/dL (1.15 mmol/L); <strong>or</strong> on lipid-lowering treatment.</li>
<li>Low HDL – HDL ≤40 mg/dL (1 mmol/L) <strong>or</strong> on lipid-lowering treatment.</li>
</ul>
<p class="extra_spacing_top">¶ UpToDate suggests using BP ≥130/80 as a cardiometabolic risk factor for children ≥13 years; this is the threshold for defining hypertension in this age group, as defined by the American Heart Association<sup>[3]</sup>. Rinella<sup>[2]</sup> used BP ≥130/85, which is the threshold for defining metabolic syndrome in adolescents that was proposed by the International Diabetes Federation in 2007 but has not been reevaluated since then.</p></div><div class="graphic_reference">References:
<ol>
<li>Rinella ME, Lazarus JV, Ratziu V, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 2023.</li>
<li>Vos MB, Abrams SH, Barlow SE, et al. NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr 2017; 64:319.</li>
<li>Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics 2017; 140:e20171904.</li>
</ol></div><div id="graphicVersion">Graphic 115653 Version 5.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
